Announcement on Receipt of the Clinical Trial Approval Notice for Shiwei Anchang Granules
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Receipt of the Clinical Trial Approval Notice for Shiwei Anchang Granules
Filed with SSE · Stock code 600557 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Story so far
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Departure of Senior Executive
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- Announcement on Receipt of the Clinical Trial Approval Notice for Qihuang Zhengqi Granules
Earlier from Jiangsu Kanion Pharmaceutical
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Departure of Senior Executive
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- Semi-annual Report for 2026
- Announcement on Receipt of the Clinical Trial Approval Notice for Qihuang Zhengqi Granules
- Announcement on Initially Repurchasing Shares through Call Auction
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical